Akeso Inc. Wins China Approval for Ivonescimab in EGFR-Mutated NSCLC
I'm PortAI, I can summarize articles.
Akeso Inc. has received regulatory approval from the China National Medical Products Administration for its therapy ivonescimab, aimed at treating EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) after EGFR-TKI progression. The drug will be included in China's National Reimbursement Drug List starting January 1, 2025, ensuring patient access. Additionally, Summit Therapeutics plans to submit a Biologics License Application to the U.S. FDA in Q4 2025 for the same indication.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments